Many studies indicate that anti-CD47 therapy can significantly enhance the treatment effect of chemotherapy and inhibit the growth of tumors; in HCC, the administration of B6H12 (anti-CD47 mAb, 10 μg/mL) was shown to augment the effect of doxorubicin and cisplatin in HCC treatment, inhibiting the macrophage-mediated phagocytosis. This evidence concerns the gene CD47 and hepatocellular carcinoma.